Title Drug Induced Diseases, 3/e
Subtitle Prevention, Detection, and Management
Author James E Tisdale, Douglas A Miller
ISBN 9781585285303
List price USD 225.00
Price outside India Available on Request
Original price
Binding Paperback
No of pages 1200
Book size 153 x 229 mm
Publishing year 2018
Original publisher ASHP - American Society of Health-System Pharmacists (Eurospan Group)
Published in India by .
Exclusive distributors Viva Books Private Limited
Sales territory India, Sri Lanka, Bangladesh, Pakistan, Nepal, .
Status New Arrival
About the book Send Enquiry
  
 

Description:

Drug-induced diseases are unintended effects of drugs that result in mortality or morbidity with symptoms sufficient to prompt a patient to seek medical attention and/or require hospitalization.
Drug-Induced Diseases provides a detailed overview of diseases that result from drug therapy, arming healthcare professionals with critical knowledge to protect the health and welfare of their patients.

Now in its third edition, this important reference helps healthcare practitioners, residents, and students by expanding the understanding of disease state causes and effects, encouraging critical thinking, and raising awareness that many diseases can be caused or exacerbated by a medication the patient is taking.

The third edition has been revised and expanded, and includes:

  • 58 peer-reviewed chapters authored by 99 contributors
  • Detailed, comprehensive tables
  • New chapters including Bleeding Disorders, Teratogenicity, and Oral Manifestations of Systemically Administered Drugs
  • Comprehensive coverage of scores of drug-induced diseases
  • Information pertaining to the contribution of genetic polymorphisms to specific drug-induced diseases
  • Levels of evidence” classification for identifying the strength of evidence that links a listed drug to a specific drug-induced disease
  • And much more


Contents:

FOREWORD

PREFACE

CONTRIBUTORS

REVIEWERS

SECTION I—MAGNITUDE/SIGNIFICANCE OF DRUG-INDUCED DISEASES: IMPACT ON THE HEALTHCARE SYSTEM

Chapter 1: Drug Safety and Drug—Induced Diseases: The Regulatory, Legal, and Practice Environments
Cynthia Reilly, MS, BS Pharm

Chapter 2: Epidemiology and Public Health Impact of Drug-Induced Diseases
John R. Litaker, PhD, MSc, MMedSc, and James P. Wilson, PharmD, PhD, FASHP

Chapter 3: Factors Contributing to Drug—Induced Diseases
Tyler Shugg, PharmD, Abdullah Assiri, PharmD, and Brian R Overholser, PharmD

Chapter 4: Postmarketing Surveillance for Drug-Induced Diseases
Tobias Peschel, MD, PhD, MBA, and Hugh H. Tilson, MD, DrPH

Chapter 5: Evaluating Patients for Drug-Induced Diseases
Douglas A. Miller, PharmD, and James E. Tisdale, PharmD, BCPS, FCCP, FAPhA, FNAP, FAHA

SECTION II—DRUG-INDUCED DERMATOLOGIC DISEASES

Chapter 6: Drug Allergy and Cutaneous Diseases
Lynne M. Sylvia, PharmD

Chapter 7: Systemic Lupus Erythematosus-Like Syndrome
Karen W. Lee, PharmD, BCPS, and Matthew F Ambury, PharmD, BCPS

Chapter 8: Photosensitivity
Julie M. Koehler, PharmD, FCCP

Chapter 9: Alopecia, Hirsutism, and Hypertrichosis
Knistine E. Keplar, PharmD

SECTION III—DRUG-INDUCED NEUROLOGICAL DISEASES

Chapter 10: Seizures
Timothy E. Welty, PharmD, FCCP, BCPS

Chapter 11: Stroke
Denise H. Rhoney, PharmD, FCCP, FCCM, FNCS

Chapter 12: Movement Disorders
Jack J. Chen, PharmD, FASCP, FCCP, BCPS, BCGP; Khashayar Dashtipour, MD, PhD; and David M Swope, MD

Chapter 13: Peripheral Neuropathy
Dennis Parker, Jr, PharmD

Chapter l4: Visual Disturbances
Yaman Kaakeh, PharmD, BCPS, BCNSP, CNSC, and Steven R. Abel, PharmD, FASHP

Chapter 15: Delirium
Matthew A. Fuller, PharmD, FASHP, BCPP

Chapter l6: Sleep Disorders
Lisa L Forsyth, PharmD, FCCM

Chapter l7: Cognitive Disorders
Michele Y Splinter, PharmD, MS, BCPS, FCCP

SECTION IV—DRUG-INDUCED PSYCHIATRIC DISEASES

Chapter l8: Depression
Sheila Botts, Pharm D, FCCP, BCPP, and Melody Ryan, Pharm D, MPH

Chapter l9: Anxiety
Julie A Dopheide, PharmD, BCPP, FASHP, and Seth Gomez, PharmD, BCPP

Chapter 20: Psychosis
Jessica L. G’oren, PharmD, BCPP

SECTION V—DRUG-INDUCED PULMONARY DISEASES

Chapter 21: Interstitial Lung Disease/Pulmonary Fibrosis
Jordan R. Covvey, PharmD, PhD, BCPS, and Erin E. Mancl, PharmD, BCPS, BCCCP

Chapter 22: Asthma and Bronchospasm
Suzanne G. Bollmeier, PharmD, BCPS, AT-C, and Rebecca L. Stauffer, PharmD, BCPS

SECTION VI—DRUG-INDUCED CARDIOVASCULAR DISEASES

Chapter 23: Myocardial Ischemia and Acute Coronary Syndromes
Kevin M. Sowinski, PharmD, FCCP

Chapter 24: Heart Failure
Yazid N. Al Hamarneh BSc(Pharm), PhD, and Ross T Tsuyuki, BSc(Pharm), PharmD, MSc, FCSHP, FACC, FCAHS

Chapter 25: Ventricular Arrhythmias
James E. Tisdale, Pharm D, BCPS, FCCP, FAPhA, FNAP, FAHA

Chapter 26: Supraventricular Arrhythmias
James E. Tisdale, PharmD, BCPS, FCCP, FAPhA, FNAP, FAHA

Chapter 27: Hypertension
Liza W. Claus, PharmD, BCACP, and Joseph J Saseen, PharmD, BCPS, BCACP, FCCP, FASHP

Chapter 28: Hypotension
Katy E. Trinkley, PharmD, BCACP, and Robert L Page II, PharmD, MSPH, BCPS (AQ-Cardiology), BCGP, FCCP, FAHA, FASHP, FHFSA

Chapter 29: Valvular and Pericardial Heart Disease
Sarah A. Spinier, PharmD, FCCP, FAHA, FASHP, AACC, BCPS (AQ-Cardiology), and Frank E. Silvestry, MD, FACC, FASE

SECTION VII—DRUG-INDUCED ENDOCRINE DISEASES

Chapter 30: Glucose and Insulin Dysregulation
Devra K. Dang, PharmD, BCPS, CDE, FNAP; Frank Pucino, Jr, PharmD, MPH, FASHP, FCCP; Charles D. Ponte, PharmD, BC-ADM, BCPS, CDE, CPE, FAADE, FAPhA, FASHP, FCCP, FNAP; and Karim Anton Calis, PharmD, MPH, FASHP, FCCP

Chapter 31: Thyroid Diseases
Genevieve Lynn Ness, PharmD; Judy T. Chen, PharmD, BCPS, BCACP, CDE, FNAP; Betty J. Dong, PharmD, FASHP, FAPhA, FCCP; Frank Pucino, Jr, PharmD, MPH, FASHP, FCCP; and Karim Anton Calis, PharmD, MPH, FASHP, FCCP

Chapter 32: Hypothalamic, Pituitary, and Adrenal Diseases
Andrew Y Hwang, PharmD, BCPS; Steven M. Smith, PharmD, MPH, BCPS; and John G. Gums, PharmD, FCCP

Chapter 33: Sexual Dysfunction in Males
Mary Lee, PharmD, BCPS, FCCP, and Roohollah Sharifi, MD, FACS

Chapter 34: Gynecologic Diseases and Infertility in Women
Judith A. Smith, PharmD, BCOP, CPHQ, FCCP, FISOPP

SECTION VIII—DRUG-INDUCED GASTROINTESTINAL DISEASES

Chapter 35: Upper Gastrointestinal Ulceration
Dianne W. May, PharmD, FCCP, BCPS; Micaela Carroll, PharmD, BCPS; and J. Russell May, PharmD, FASHP

Chapter 36: Diarrhea
Sarah A. Nisly, PharmD, BCPS, FCCP, and Alison M. Walton, PharmD, BCPS

Chapter 37: Constipation
Sarah A. Nisly, PharmD, BCPS, FCCP, and Carolyn M. Jung, PharmD, BCPS

Chapter 38: Hepatic and Cholestatic Diseases
Scott S. Malinowski, PharmD, and Daniel M. Riche, PharmD, FCCP, BCPS, CDE, ASH-CHC, CLS

Chapter 39: Pancreatitis
Pramodini B. Kale-Pradhan, PharmD, and Sheila M. Wilhelm, PharmD, FCCP, BCPS

Chapter 40: Nausea and Vomiting
Saeed K. Alzghari, MS, MBA (HOM), Pharma BCPS; Bonnie A. Labdi, PharmD, BCP, and Jon D Herrington, PharmD, BCPS, BCOP

SECTION IX-DRUG-INDUCED DISEASES OF THE KIDNEY AND FLUID & ELECTROLYTE DISORDERS

Chapter 41: Acute Kidney Injury
Amy Barton Pai, PharmD, BCPS, FASN, FCCR FNKF, and Nicole M. Wegrzyn, PharmD, BCACP

Chapter 42: Chronic Kidney Disease
Mary. K Stamatakis, PharmD

Chapter 43: Syndrome of Inappropriate Antidiuretic Hormone Secretion and Diabetes Insipidus
Mark A. Malesker, PharmD, FCCR FCCM, FASHR BCPS, and Daniel E. Hillman, PharmD, FCCP

Chapter 44: Acid-Base Disorders
Lori D Wazny, BSc(Pharm), PharmD, EPA; Christine Davis, BSc(Pharm), PharmD, ACPR and Robert E. Ariano, PharmD, BCPS, FCCM

SECTION X-DRUG-INDUCED HEMATOLOGICAL DISORDERS

Chapter 45: Bleeding Disorders
Tiffany Pon, PharmD, BCPS, and Jaekyu Shin, PharmD, MS, BCPS

Chapter 46: Thrombocytopenia
Kerne Jones Weddle, PharmD, BCOR FCCP; FHOPA, and Patrick J. Kiel, PharmD, BCPS, BCOP

Chapter 47: Thromboembolic Diseases
Candice L. Garwood, PharmD, FCCP, BCPS, BCACP

Chapter 48: Neutropenia and Agranulocytosis
Teresa C. Thakrar, PharmD, BCOP, and Christopher A. Fausel, PharmD, MHA, BCOP

Chapter 49: Anemias
LeAnn B. Norris, PharmD, BCPS, BCOP, and Charles L. Bennett, MD, PhD, MPP

SECTION XI-DRUG-INDUCED BONE, JOINT, AND MUSCLE DISEASES

Chapter 50: Osteoporosis and Osteomalacia
Laura M. Borgelt, PharmD, FCCP, BCPS, and Danielle R. Fixers, PharmD

Chapter 51: Gout and Hyperuricemia
Jasmine D. Gonzalvo, PharmD, BCPS, BC-ADM, CDE, LDE

Chapter 52: Myopathy
Craig Williams, PharmD, FLNA, BCPS

SECTION XII-MI-MISCELLANEOUS DRUG-INDUCED DISEASES

Chapter 53: Weight Gain
Amy Heck Sheehan, PharmD

Chapter 54: Temperature Dysregulation
Susan M. Wilson, PharmD, and Ian A Ross, PharmD

Chapter 55: Ototoxicity
Monica L. Miller, PharmD, MS

Chapter 56: Oral Manifestations of Systemically Administered Drugs
Ashley H. Meredith, PharmD, BCACP, BCPS, CDE

Chapter 57: Neoplastic Diseases
Sandra Cuellar, PharmD, BCOP, and Christina Mactal Haaf, PharmD, BCOP, BCPS

Chapter 58: Teratogenicity
Kylie N. Barnes, PharmD, BCPS

INDEX


Target Audience:

This book is the must-have resource for pharmacists, physicians, nurses, and pharmacy students alike.

 

 
Special prices are applicable to the authorised sales territory only.
Prices are subject to change without prior notice.